Urothelial Cancer Clinical Trials

142 clinical trials for Urothelial Cancer across international registries, including 54 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) — RECRUITING · PHASE2
• Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue — RECRUITING
• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies — RECRUITING
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) — RECRUITING · PHASE3
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — RECRUITING · PHASE1
• BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) — RECRUITING · PHASE1
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy — RECRUITING · PHASE2
• DK222 Study at Hopkins — RECRUITING · PHASE1
• Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma — RECRUITING · PHASE2
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer — RECRUITING · PHASE1
• A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection — RECRUITING
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies — RECRUITING · PHASE2
• A PHASE III, OPEN-LABEL, RANDOMISED, MULTICENTRE, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN IN COMBINATION WITH RILVEGOSTOMIG IN PARTICIPANTS WITH HIGH-RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA (TROPION-UROTHELIAL04) — RECRUITING · PHASE3
• AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) — RECRUITING · PHASE1
• SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN (MK-2870) CARCINOMA VERSUS INVESTIGATOR’S CHOICE OF NON-PLATINUM CHEMOTHERAPY IN PARTICIPANTS WITH PRETREATED LOCALLY ADVANCED/METASTATIC UROTHELIAL — RECRUITING · PHASE3
• Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma — RECRUITING
• Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer — RECRUITING
• Sacituzumab Govitecan Plus EV in Metastatic UC — RECRUITING · PHASE1
• IZABRIGHT-BLADDER01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER IN PARTICIPANTS WITH DISEASE PROGRESSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT — RECRUITING · PHASE2
• A PHASE 1/2, SINGLE-ARM, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF NADOFARAGENE FIRADENOVEC INSTILLED TO THE RENAL PELVIS IN ADULT SUBJECTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC) — RECRUITING · PHASE1
• MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRDBASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER — RECRUITING · PHASE3
• A RANDOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (DURAVELO-2) — RECRUITING · PHASE2
• A PHASE 2/3 MULTICENTER TRIAL EVALUATING THE SAFETY AND EFFICACY OF ST-02 ON ABLATION OF UROTHELIAL CARCINOMAS IN THE UPPER URINARY TRACT — RECRUITING · PHASE2
• PREVENTING INTRAVESICAL RECURRENCE IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT: A PILOT RANDOMIZED TRIAL OF A SINGLE PROPHYLACTIC BLADDER INSTILLATION OF MITOMYCIN C AFTER DIAGNOSTIC URETEROSCOPY — RECRUITING
• AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBO WITH PEMBROLIZUMAB VS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HERS2 (1HC1 + AND GREATER) — RECRUITING · PHASE3
• A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS INCLUDING UROTHELIAL CANCER WITH FGFR3 ALTERATIONS — RECRUITING · PHASE1
• A PHASE 1/2 OPEN-LABEL ROLLING-ARM UMBRELLA PLATFORM STUDY OF INVESTIGATIONAL AGENTS WITH OR WITHOUT PEMBROLIZUMAB IN PARTICIPANTS WITH UROTHELIAL CARCINOMA (KEYMAKER-U04): MASTER PROTOCOL — RECRUITING · PHASE1
• MAIN-CAV: PHASE III RANDOMIZED TRIALS OF MAINTENANCE CABOZANTINIB AND AVELUMAB VS MAINTENANCE AVELUMAB AFTER FIRST-LINE PLATINUM BASED CHEMOTHERAPY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER — RECRUITING · PHASE3
• A PHASE II, MULTICENTER, RANDOMIZED, OPEN LABEL, PARALLEL-ARM, UMBRELLA STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS AS A MAINTENANCE TREATMENT IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHOSE DISEASE DID NOT PROGRESS WITH FIRST LINE PLATINUMCONTAINING CHEMOTHERAPY — RECRUITING · PHASE2
• A PHASE 2 MULTI COHORT, OPEN LABEL, MULTI CENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN (RC48 ADC) IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA — RECRUITING · PHASE2
• A PHASE II RANDOMIZED TRIAL OF BICALUTAMIDE VS PLACEBO IN PATIENTS RECEIVING INTRAVESICAL BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER — RECRUITING · PHASE2
• PHASE III STUDY OF SACITUZUMAB GOVITECAN (IMMU-132) IN METASTATIC OR LOCALLY ADVANCED UNRESECTABLE UROTHELIAL CANCER — RECRUITING · PHASE3
• A STUDY OF ENFORTUMAB VEDOTIN (ASG-22CE) AS MONOTHERAPY OR IN COMBINATION WITH ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER — RECRUITING
• A PHASE IB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BINTRAFUSP ALFA MONOTHERAPY IN METASTATIC OR LOCALLY ADVANCED/UNRESECTABLE UROTHELIAL CANCER WITH DISEASE PROGRESSION OR RECURRENCE FOLLOWING TREATMENT WITH A PLATINUM AGENT. — RECRUITING · PHASE1
• NEOADJUVANT CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CANCER (NAUTICAL): A MULTICENTRE, FEASIBILITY PILOT TRIAL — RECRUITING
• A PHASE, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH LENVATINIB (E7080/MK-7902) VERSUS PEMBROLIZUMAB AND PLACEBO AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN CISPLATIN-INELIGIBLE PARTICIPANTS WHOSE TUMORS EXPRESS PD-L1, AND IN PARTICIPANTS INELIGIBLE FOR ANY PLATINUM-CONTAINING CHEMOTHERAPY REGARDLESS OF PD-L1 EXPRESSION (LEAP-011) — RECRUITING
• PHASE 2 MULTICENTER TRIAL OF ICOS AGONIST MONOCLONAL ANTIBODY (MAB) JTX-2011 AND A CTLA-4 INHIBITOR IN PD-1/PD-L1 INHIBITOR EXPERIENCED ADULT SUBJECTS WITH NON-SMALL CELL LUNG CANCER OR UROTHELIAL CANCER — RECRUITING · PHASE2
• A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER, GLOBAL STUDY OF FIRST-LINE DURVALUMAB IN COMBINATION WITH STANDARD OF CARE CHEMOTHERAPY AND DURVALUMAB IN COMBINATION WITH TREMELIMUMAB AND STANDARD OF CARE CHEMOTHERAPY VERSUS STANDARD OF CARE CHEMOTHERAPY ALONE IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (NILE) — RECRUITING · PHASE3
• A PHASE II, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, COMPARATIVE GLOBAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DURVALUMAB IN COMBINATION WITH OLAPAIB FOR FIRST-LINE TREATMENT IN CISPLATIN-INELIGIBLE PATIENTS WITH UNRESECTABLE STAGE IV UROTHELIAL CANCER (BAYOU) — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF PEMBROLIZUMAB + EPACADOSTAT VS PEMBROLIZUMAB + PLACEBO AS A TREATMENT FOR RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CARCINOMA IN PATIENTS WHO HAVE FAILED A FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN FOR ADVANCED/METASTATIC DISEASE (KEYNOTE-698/ECHO-303) — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND TRIAL OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH EPACADOSTAT (INCB024360) OR PLACEBO IN PARTICIPANTS WITH CISPLATIN INELIGIBLE UROTHELIAL CARCINOMA (KEYNOTE-672/ECHO-307) — RECRUITING · PHASE3
• LONG TERM FOLLOW-UP OF SUBJECTS EXPOSED TO GENETICALLY ENGINEERED TUMOR ANTIGEN SPECIFIC T CELL RECEPTORS — RECRUITING
• A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF MGA271 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH MELANOMA, SQUAMOUS CELL CANCER OF THE HEAD AND NECK, NON-SMALL CELL LUNG CANCER, UROTHELIAL CANCER, AND OTHER CANCERS — RECRUITING · PHASE1
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CANCER — RECRUITING · PHASE3
• A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS MONOTHERAPY AND IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY OF ADJUVANT NIVOLUMAB VERSUS PLACEBO IN SUBJECTS WITH HIGH RISK INVASIVE UROTHELIAL CARCINOMA — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER, GLOBAL STUDY OF FIRST-LINE MEDI4736 MONOTHERAPY AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE STAGE IV UROTHELIAL BLADDER CANCER — RECRUITING · PHASE3
• MPACT OF POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER STAGING (PETMUSE) — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY — RECRUITING · PHASE3

Refine this search